Utilizing Pharmacogenomics Results to Determine Opioid Appropriateness and Improve Pain Management in a Patient with Osteoarthritis

References

• Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American college of rheumatology/arthritis foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Care Res. 2020;72(2):149–162. doi:10.1002/acr.24131
   PubMed Web of Science ®Google Scholar
• Buffum M, Buffum JC. Nonsteroidal anti-inflammatory drugs in the elderly. Pain Manag Nurs. 2000;1(2):40–50. doi:10.1053/jpmn.2000.7779
   PubMedGoogle Scholar
• Eapen-John D, Mohiuddin AG, Kennedy JL. A potential paradigm shift in opioid crisis management: the role of pharmacogenomics. World J Biol Psychiatry. 2021;11:1–19.
   Google Scholar
• Bright DR, Petry N, Roath E, Gibb T. Engaging pharmacogenomics in pain management and opioid selection. Pharmacogenomics. 2021;22(14):927–937. doi:10.2217/pgs-2021-0044
   PubMed Web of Science ®Google Scholar
• Rodriguez Cairoli F, Appiani F, Sambade JM, Comandé D, Camacho Arteaga L, Ciapponi A. Efficacy and safety of opioid therapy guided by pharmacogenetics (PGx): a systematic review. Pharmacogenomics. 2021;22(9):573–586. doi:10.2217/pgs-2021-0021
   PubMed Web of Science ®Google Scholar
• Schuh MJ, Randles H, Crosby S. Improving pain management with pharmacogenomics: a general introduction. J Pain Palliat Care Pharmacother. 2020;34(3):114–119. doi:10.1080/15360288.2020.1734140
   PubMed Web of Science ®Google Scholar
• Lemke AA, Hutten Selkirk CG, Glaser NS, et al. Primary care physician experiences with integrated pharmacogenomic testing in a community health system. Per Med. 2017;14(5):389–400. doi:10.2217/pme-2017-0036
   PubMed Web of Science ®Google Scholar
• Magarbeh L, Gorbovskaya I, Le Foll B, Jhirad R, Müller DJ. Reviewing pharmacogenetics to advance precision medicine for opioids. Biomed Pharmacother. 2021;142:112060. doi:10.1016/j.biopha.2021.112060
   PubMed Web of Science ®Google Scholar
• Crews KR, Monte AA, Huddart R, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. Clin Pharmacol Ther. 2021;110(4):888–896. doi:10.1002/cpt.2149
   PubMed Web of Science ®Google Scholar
• Brandl E, Halford Z, Clark MD, Herndon C. Pharmacogenomics in pain management: a review of relevant gene-drug associations and clinical considerations. Ann Pharmacother. 2021;55:1486–1501.
   PubMed Web of Science ®Google Scholar
• Deodhar M, Turgeon J, Michaud V. Contribution of CYP2D6 functional activity to oxycodone efficacy in pain management: genetic polymorphisms, phenoconversion, and tissue-selective metabolism. Pharmaceutics. 2021;13(9):9. doi:10.3390/pharmaceutics13091466
   Web of Science ®Google Scholar
• Michaud V, Smith MK, Bikmetov R, et al. Association of the MedWise Risk Score with health care outcomes. Am J Manag Care. 2021;27(16 Suppl):S280–S291.
   PubMed Web of Science ®Google Scholar
• Deodhar M, Al Rihani SB, Arwood MJ, et al. Mechanisms of CYP450 inhibition: understanding drug-drug interactions due to mechanism-based inhibition in clinical practice. Pharmaceutics. 2020;12:9. doi:10.3390/pharmaceutics12090846
   Web of Science ®Google Scholar
• Hirota T, Fujita Y, Ieiri I. An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. Expert Opin Drug Metab Toxicol. 2020;16(9):809–822. doi:10.1080/17425255.2020.1801634
   PubMed Web of Science ®Google Scholar
• Krasulova K, Holas O, Anzenbacher P. Influence of amlodipine enantiomers on human microsomal cytochromes p450: stereoselective time-dependent inhibition of CYP3A enzyme activity. Molecules. 2017;22:11. doi:10.3390/molecules22111879
   Web of Science ®Google Scholar
• Cohen B, Preuss CV. Celecoxib. In: StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC; 2022.
   Google Scholar
• Theken KN, Lee CR, Gong L, et al. Clinical pharmacogenetics implementation consortium Guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs. Clin Pharmacol Ther. 2020;108(2):191–200. doi:10.1002/cpt.1830
   PubMed Web of Science ®Google Scholar
• Gong L, Stamer UM, Tzvetkov MV, Altman RB, Klein TE. PharmGKB summary: tramadol pathway. Pharmacogenet Genomics. 2014;24(7):374–380. doi:10.1097/FPC.0000000000000057
   PubMed Web of Science ®Google Scholar
• Stamer UM, Musshoff F, Kobilay M, Madea B, Hoeft A, Stuber F. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin Pharmacol Ther. 2007;82(1):41–47. doi:10.1038/sj.clpt.6100152
   PubMed Web of Science ®Google Scholar
• Takeshita J, Litzinger MH. Serotonin syndrome associated with tramadol. Prim Care Companion J Clin Psychiatry. 2009;11(5):273. doi:10.4088/PCC.08l00690
   PubMedGoogle Scholar
• Dean LKM. Tramadol therapy and CYP2D6 genotype. In: Pravatt VM, Pirmohamed M, editors. Medical Genetics Summaries [Internet]. Bethesada (MD): National Center for Biotechnology Information; 2015.
   Google Scholar
• Lassen D, Damkier P, Brosen K. The pharmacogenetics of tramadol. Clin Pharmacokinet. 2015;54(8):825–836. doi:10.1007/s40262-015-0268-0
   PubMed Web of Science ®Google Scholar
• Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther. 2006;79(5):461–479. doi:10.1016/j.clpt.2006.01.009
   PubMed Web of Science ®Google Scholar
• Lalovic B, Phillips B, Risler LL, Howald W, Shen DD. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004;32(4):447–454. doi:10.1124/dmd.32.4.447
   PubMed Web of Science ®Google Scholar
• Heiskanen T, Olkkola KT, Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther. 1998;64(6):603–611. doi:10.1016/S0009-9236(98)90051-0
   PubMed Web of Science ®Google Scholar
• Matic M, Nijenhuis M, Soree B, et al. Correction: Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone). Eur J Hum Genet. 2021;30(10):1105–1113. doi:10.1038/s41431-021-00920-y
   PubMed Web of Science ®Google Scholar
• Samer CF, Daali Y, Wagner M, et al. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br J Pharmacol. 2010;160(4):919–930. doi:10.1111/j.1476-5381.2010.00709.x
   PubMed Web of Science ®Google Scholar
• Holzer P. Opioid receptors in the gastrointestinal tract. Regul Pept. 2009;155(1–3):11–17. doi:10.1016/j.regpep.2009.03.012
   PubMed Web of Science ®Google Scholar
• Galligan JJ, Sternini C. Insights into the role of opioid receptors in the GI tract: experimental evidence and therapeutic relevance. Handb Exp Pharmacol. 2017;239:363–378.
   PubMedGoogle Scholar
• Stiller CO, Hjemdahl P. Lessons from 20 years with COX-2 inhibitors: importance of dose-response considerations and fair play in comparative trials. J Intern Med. 2022;292(4):557–574. doi:10.1111/joim.13505
   PubMed Web of Science ®Google Scholar
• Zanger UM, Klein K. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front Genet. 2013;4:24. doi:10.3389/fgene.2013.00024
   PubMedGoogle Scholar